Francis Baumgartner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francis Baumgartner has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Ulrich Keller
Department of Hematology, Oncology and Cancer Immunology Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu Berlin Berlin Germany
20 shared publications - Matthias Wirth
Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany
18 shared publications - Jan Braune
Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin, Germany
17 shared publications - Jan Krönke
Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany
17 shared publications - Stefan Habringer
Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité -Universitätsmedizin Berlin, Berlin, Germany
17 shared publications - Amelie Gasper
Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin, Germany
16 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Society of Hematology in Blood
Upfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes
Inherited bone marrow failure syndromes (IBMFS) are monogenic disorders characterized by single or multilineage cytopenias from hypoproliferative dyshematopoiesis. Diagnosis is challenging because of substantial clinical and pathological overlap between individual IBMFS entities and acquired diseases such as immune aplastic anemia. Conventional genetic testing using targeted panels or whole exome sequencing incompletely captures the spectrum of pathogenic variation, leaving a substantial proportion of cases undiagnosed. We evaluated the utility of upfront whole genome and transcriptome sequencing (WGTS) in 237 patients with suspected IBMFS using non-hematopoietic DNA. Median age was 29 years (range 3 months-76 years) and 34.6% were under 18 years. Clinically-accredited sequencing was performed with real-time return of results to guide patient management and familial testing. A molecular diagnosis was established in 87/237 patients (36.7%), spanning hereditary thrombocytopenia, telomere biology disorders, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, Fanconi anemia and other IBMFS. A further four patients were diagnosed with non-hematological genetic conditions and seven patients with secondary actionable findings. Novel pathogenic mechanisms including retrotransposon-mediated gene disruption were identified. Further, novel associations with primary IBMFS-like presentations (THRA) as well as definitive evidence of gene-disease associations (MEIS1, TUBB) were established. Acceptability of WGTS based on the established Theoretical Framework of Acceptability was high among patients and carers. Upfront WGTS in suspected IBMFS provides a high diagnostic yield when compared with other genomic approaches, identifies actionable genomic abnormalities, and expands the spectrum of disease mechanisms and gene associations in IBMFS.
- 5 November 2026
- Published by American Society of Hematology in Blood
Open AccessUpfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes
Inherited bone marrow failure syndromes (IBMFS) are monogenic disorders characterized by single or multilineage cytopenias from hypoproliferative dyshematopoiesis. Diagnosis is challenging because of substantial clinical and pathological overlap between individual IBMFS entities and acquired diseases such as immune aplastic anemia. Conventional genetic testing using targeted panels or whole exome sequencing incompletely captures the spectrum of pathogenic variation, leaving a substantial proportion of cases undiagnosed. We evaluated the utility of upfront whole genome and transcriptome sequencing (WGTS) in 237 patients with suspected IBMFS using non-hematopoietic DNA. Median age was 29 years (range 3 months-76 years) and 34.6% were under 18 years. Clinically-accredited sequencing was performed with real-time return of results to guide patient management and familial testing. A molecular diagnosis was established in 87/237 patients (36.7%), spanning hereditary thrombocytopenia, telomere biology disorders, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, Fanconi anemia and other IBMFS. A further four patients were diagnosed with non-hematological genetic conditions and seven patients with secondary actionable findings. Novel pathogenic mechanisms including retrotransposon-mediated gene disruption were identified. Further, novel associations with primary IBMFS-like presentations (THRA) as well as definitive evidence of gene-disease associations (MEIS1, TUBB) were established. Acceptability of WGTS based on the established Theoretical Framework of Acceptability was high among patients and carers. Upfront WGTS in suspected IBMFS provides a high diagnostic yield when compared with other genomic approaches, identifies actionable genomic abnormalities, and expands the spectrum of disease mechanisms and gene associations in IBMFS.
- Open Access
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2221-2228
CAR transgenic T-cell lymphoproliferative neoplasm: malignant transformation of cellular immunotherapy
Engineered T cells have transformed hemato-oncology, but chimeric antigen receptor (CAR) transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR T-cell therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR T-cell manufacture, vector integration, construct biology, and postinfusion selection may contribute to different degrees. We review reported cases of CAR transgenic T-cell lymphoproliferative neoplasms and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2221-2228
Open AccessCAR transgenic T-cell lymphoproliferative neoplasm: malignant transformation of cellular immunotherapy
Engineered T cells have transformed hemato-oncology, but chimeric antigen receptor (CAR) transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR T-cell therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR T-cell manufacture, vector integration, construct biology, and postinfusion selection may contribute to different degrees. We review reported cases of CAR transgenic T-cell lymphoproliferative neoplasms and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC and KANSL2 co-regulated targets and their functions
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC and KANSL2 co-regulated targets and their functions
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 influences the level of H3K27ac
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
KANSL2 influences the level of H3K27ac
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC induces KANSL2 RNA and protein expression
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
MYC induces KANSL2 RNA and protein expression
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Panobinostat and OTX015 act synergistically in high KANSL2 MM cells
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma
Panobinostat and OTX015 act synergistically in high KANSL2 MM cells